Open access

Impact of PD‐1 Inhibitor Timing Relative to Locoregional Therapy on Outcomes in uHCC Treated With Lenvatinib‐Based Triple Therapy

Jian He Jian Chen Bo-Hua Yu Fu-Qun Wei Wei-Fu Liu Pei Huang Song-Hui Wu Xiang You Zhi-Sheng Chen Zi-Qi Lin Wu-Hua Guo Shao-Wu Zhuang Yi-Ping Chen Zhong-Wu Chen

Aug 2026 · Liver international (Print) · Vol 46 · 1 citation · 27 references

Medicine

TL;DR

This study evaluated the impact of PD‐1 inhibitor timing on outcomes in patients receiving hepatic arterial infusion chemotherapy (HAIC) or transarterial chemoembolisation (TACE) plus lenvatinib and PD‐1 inhibitors.

Abstract

The optimal sequencing of programmed cell death protein 1 (PD‐1) inhibitors relative to locoregional therapy (LRT) in unresectable hepatocellular carcinoma (uHCC) remains undefined. This study evaluated the impact of PD‐1 inhibitor timing on outcomes in patients receiving hepatic arterial infusion chemotherapy (HAIC) or transarterial chemoembolisation (TACE) plus lenvatinib and PD‐1 inhibitors.

DOI PubMed Semantic Scholar

Read PDF

Similar papers

Open access Sep 2026

Survival Outcomes With Cadonilimab Versus PD‐(L)1 Therapy in Front‐Line Gastric Cancer: A Network Meta‐Analysis

The FDA Oncologic Drugs Advisory Committee (ODAC) highlighted that the risk–benefit profile for patients with low PD‐L1 expression remains unclear in front‐line treatment of HER2‐negative gastric and gastroesophageal junction (GC/GEJ) cancer with PD‐(L)1 therapy. The first PD‐1/CTLA‐4 bispecific antibody (BsAb), cadoni...

Zi-Kun Yu, Jia-Hong Yi, Ju Xue et al. · Cancer Reports · 0 citations

Open access Sep 2026

PD‐1 Inhibitor (Sintilimab) Combined With Chemotherapy as Neoadjuvant Therapy in Advanced Ovarian Cancer: A Case Report

In a patient with advanced ovarian cancer showing limited response to paclitaxel–carboplatin, adding sintilimab was associated with R0 cytoreduction and sustained disease‐free status during olaparib–bevacizumab maintenance. This case provides a rationale for further investigation of PD‐1 blockade as neoadjuvant therapy...

Zhen-Yan Wang, Yan Wang · Clinical Case Reports · 1 citation

Open access Sep 2026

Rechallenge With Immunotherapy for ES‐SCLC: Efficacy and Safety From a Retrospective Propensity Score‐Matched Study

Although immunotherapy combined with platinum‐based chemotherapy is now the standard first‐line treatment for extensive‐stage small cell lung cancer (ES‐SCLC), the benefit of continuing immune checkpoint inhibitors (ICIs) after disease progression (PD) remains uncertain. This real‐world study assessed the efficacy and...

Yu-Xia Wang, Yun-Feng Tong, Yang Pan et al. · Cancer Medicine · 0 citations

Open access Oct 2026

Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database

Patients with chemotherapy‐ and androgen receptor pathway inhibitor (ARPI)‐naïve metastatic castration‐resistant prostate cancer (mCRPC) have generally shown worse overall survival (OS) with abiraterone versus enzalutamide in claims database studies. Given limitations of claims data, analysis using detailed electronic...

D. George, J. Ivanova, M. Touya et al. · Cancer Medicine · 0 citations

Open access Oct 2026

Survival Outcomes With Lu-177 PSMA by Treatment Line and Taxane Sequencing in Prostate Cancer

This cohort study examines time to next treatment and overall survival associated with initiation of lutetium Lu 177 vipivotide tetraxetan (Lu-177) prostate-specific membrane antigen (PSMA) among US patients with metastatic androgen pathway modulator–resistant prostate cancer.

Varun Nandakumar, Y. Jo, M. Ostrowski et al. · JAMA Network Open · 0 citations

Review Open access Sep 2026

Sintilimab Combined With Albumin‐Bound Paclitaxel and SOX Regimen as Conversion Therapy for Unresectable Advanced Gastric Cancer Achieving Complete Remission: A Case Report and Literature Review

For carefully selected patients with unresectable advanced gastric cancer, immunochemotherapy combining PD‐1 inhibitor with albumin‐bound paclitaxel and S‐1/oxaliplatin may achieve deep remission and enable successful R0 resection. Our findings suggest that this multimodal conversion approach could be considered in sel...

Yu-Fan Tang, Bo-Quan Zhou, B.-B. Wen et al. · Clinical Case Reports · 0 citations